[go: up one dir, main page]

CA3003899A1 - Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof - Google Patents

Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof Download PDF

Info

Publication number
CA3003899A1
CA3003899A1 CA3003899A CA3003899A CA3003899A1 CA 3003899 A1 CA3003899 A1 CA 3003899A1 CA 3003899 A CA3003899 A CA 3003899A CA 3003899 A CA3003899 A CA 3003899A CA 3003899 A1 CA3003899 A1 CA 3003899A1
Authority
CA
Canada
Prior art keywords
seq
il1rap
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3003899A
Other languages
English (en)
French (fr)
Inventor
Bradley J. HEIDRICH
Jennifer F. NEMETH
Walter K. Nishioka, Jr.
Thai Dinh
Rosa Maria Fernandes CARDOSO
Darlene PIZUTTI
Brandy STRAKE
Jamie Fisher
Ricardo Marcos ATTAR
Francois Gaudet
Mark E. Salvati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3003899A1 publication Critical patent/CA3003899A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3003899A 2015-11-02 2016-11-01 Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof Abandoned CA3003899A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249466P 2015-11-02 2015-11-02
US62/249,466 2015-11-02
PCT/US2016/059842 WO2017079121A2 (en) 2015-11-02 2016-11-01 Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof

Publications (1)

Publication Number Publication Date
CA3003899A1 true CA3003899A1 (en) 2017-05-11

Family

ID=57286884

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003899A Abandoned CA3003899A1 (en) 2015-11-02 2016-11-01 Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof

Country Status (25)

Country Link
US (2) US20170121420A1 (es)
EP (1) EP3371220A2 (es)
JP (1) JP2018534933A (es)
KR (1) KR20180072820A (es)
CN (1) CN108431042A (es)
AR (1) AR106555A1 (es)
AU (1) AU2016350705A1 (es)
BR (1) BR112018008908A2 (es)
CA (1) CA3003899A1 (es)
CL (1) CL2018001175A1 (es)
CO (1) CO2018005695A2 (es)
CR (1) CR20180250A (es)
EA (1) EA201891084A1 (es)
EC (1) ECSP18040535A (es)
IL (1) IL259082A (es)
JO (1) JO3800B1 (es)
MA (1) MA43164A (es)
MX (1) MX2018005545A (es)
NI (1) NI201800057A (es)
PE (1) PE20181310A1 (es)
PH (1) PH12018500938A1 (es)
SG (1) SG11201803675RA (es)
TW (1) TW201734045A (es)
UY (1) UY36974A (es)
WO (1) WO2017079121A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
RU2597831C2 (ru) 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EP4331585A3 (en) 2015-11-02 2024-05-15 Blueprint Medicines Corporation Inhibitors of ret
CN108348603B (zh) * 2015-11-03 2023-12-29 Ambrx公司 抗cd3叶酸结合物和其用途
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CN110997725B (zh) 2017-06-12 2024-08-09 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
CN111246882A (zh) 2017-08-01 2020-06-05 希望之城 抗il1rap抗体
EP3489259A1 (en) * 2017-11-23 2019-05-29 Etablissement Français du Sang Anti-il-1rap-car-t cells and their use
WO2019195471A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof
JP2022532812A (ja) 2018-08-16 2022-07-20 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体組成物
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11884719B2 (en) * 2018-12-21 2024-01-30 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
US20230295313A1 (en) * 2019-06-26 2023-09-21 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
CA3192323A1 (en) 2020-09-14 2022-03-17 Julie MACOIN Antibodies that bind to il1rap and uses thereof
WO2022170008A2 (en) * 2021-02-05 2022-08-11 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
AR130550A1 (es) * 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso
CN116574189A (zh) * 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1538206E (pt) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Método para a síntese química e construção completa de genes e genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res (Munich) Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
LT2520590T (lt) 2007-04-03 2018-09-10 Amgen Research (Munich) Gmbh Susijusioms rūšims specifinis rišantis domenas
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US8709715B2 (en) 2008-03-26 2014-04-29 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
PT2356153T (pt) 2008-10-01 2016-07-15 Amgen Res (Munich) Gmbh Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
EP3375790A1 (en) 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
WO2010037837A2 (en) 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
RS65965B1 (sr) 2010-04-20 2024-10-31 Genmab As Proteini koji sadrže fc heterodimernih antitela i postupci njihove proizvodnje
KR101973930B1 (ko) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Fc 도메인 내의 돌연변이를 갖는 안정한 이종이량체 항체 디자인
RU2597831C2 (ru) * 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
RS62689B1 (sr) 2011-11-04 2021-12-31 Zymeworks Inc Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu
CN110042105B (zh) 2012-12-14 2023-03-28 欧莫诺艾比公司 编码具有人独特型的啮齿动物抗体的多核苷酸以及包含所述多核苷酸的动物
US20150315279A1 (en) 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof

Also Published As

Publication number Publication date
US20170121420A1 (en) 2017-05-04
IL259082A (en) 2018-06-28
CO2018005695A2 (es) 2018-06-12
EA201891084A1 (ru) 2019-10-31
CR20180250A (es) 2018-10-01
CL2018001175A1 (es) 2018-10-12
MX2018005545A (es) 2019-02-20
ECSP18040535A (es) 2018-06-30
UY36974A (es) 2017-05-31
EP3371220A2 (en) 2018-09-12
US20190270826A1 (en) 2019-09-05
AR106555A1 (es) 2018-01-24
JO3800B1 (ar) 2021-01-31
AU2016350705A1 (en) 2018-05-17
WO2017079121A2 (en) 2017-05-11
CN108431042A (zh) 2018-08-21
PH12018500938A1 (en) 2018-11-19
SG11201803675RA (en) 2018-05-30
TW201734045A (zh) 2017-10-01
KR20180072820A (ko) 2018-06-29
MA43164A (fr) 2018-09-12
JP2018534933A (ja) 2018-11-29
PE20181310A1 (es) 2018-08-10
NI201800057A (es) 2018-08-24
BR112018008908A2 (pt) 2018-11-27
WO2017079121A3 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
US20190270826A1 (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
US11884722B2 (en) Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
US10072088B2 (en) Anti-BCMA antibodies and uses thereof
US9850310B2 (en) CD123 binding agents and uses thereof
JP2024507180A (ja) Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
EA044685B1 (ru) Антитела к gprc5d, биспецифические антигенсвязывающие молекулы, которые связывают gprc5d и cd3, и их применение

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230124

FZDE Discontinued

Effective date: 20230124